Nutriband (Nutriband) ROCE % : -103.78% (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nutriband ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nutriband's annualized ROCE % for the quarter that ended in Jan. 2024 was -103.78%.

Nutriband ROCE % Historical Data

The historical data trend for Nutriband's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband ROCE % Chart

Nutriband Annual Data

Trend

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

ROCE %

Get a 7-Day Free Trial

-205.19

-70.40

-62.72

-43.30

-71.05

Nutriband Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															-72.48	-48.77	-38.84	-81.89	-103.78

Nutriband ROCE % Calculation

Nutriband's annualized ROCE % for the fiscal year that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jan. 2024 )		(A: Jan. 2023 )		(A: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jan. 2024 )		(A: Jan. 2023 )		(A: Jan. 2024 )
	=	-5.409	/	( ( (9.456 - 0.749)	+	(7.517 - 0.999) )	/ 2 )
	=	-5.409	/	( (8.707	+	6.518)	/ 2 )
	=	-5.409	/	7.6125
	=	-71.05 %

Nutriband's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-7.432	/	( ( (8.523 - 0.718)	+	(7.517 - 0.999) )	/ 2 )
	=	-7.432	/	( ( 7.805	+	6.518 )	/ 2 )
	=	-7.432	/	7.1615
	=	-103.78 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Nutriband (NAS:NTRB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nutriband ROCE % Related Terms

Thank you for viewing the detailed overview of Nutriband's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutriband (Nutriband) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

9WV:Germany

Address

121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801

Website

https://www.nutriband.com

Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Executives

Michael Davidov	director	60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik	director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan	director, 10 percent owner, officer: CEO	6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros	director, 10 percent owner, officer: Chairman of the BOD	GREGERSTR 36B, FISHAMEND C4 2401